Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher N Johnson

Showing results (121-130 of 146) with videos related to

Pageof 15
Sort By:
Journal of Medicinal Chemistry|November 29, 2014
Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profilesJohn Skidmore, Jag Heer, Christopher N Johnson, et al.
Journal of Medicinal Chemistry|July 29, 2015
Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAPGianni Chessari, Ildiko M Buck, James E H Day, et al.
Nature Communications|January 30, 2016
Climate change not to blame for late Quaternary megafauna extinctions in AustraliaFrédérik Saltré, Marta Rodríguez-Rey, Barry W Brook, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinaseChristopher N Johnson, Valerio Berdini, Lijs Beke, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper KinaseChristopher N Johnson, Christophe Adelinet, Valerio Berdini, et al.
Journal of Medicinal Chemistry|August 10, 2018
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)Christopher N Johnson, Jong Sook Ahn, Ildiko M Buck, et al.
Journal of Medicinal Chemistry|October 31, 2003
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonistGregor J Macdonald, Clive L Branch, Michael S Hadley, et al.
Structure (London, England : 1993)|June 18, 2025
High throughput cryo-EM provides structural understanding for modulators of the lysosomal ion channel TRPML1Judith Reeks, Pravin Mahajan, Mellissa Clark, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2005
Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonistsMahmood Ahmed, Michael A Briggs, Steven M Bromidge, et al.
Circulation|February 8, 2013
Calmodulin mutations associated with recurrent cardiac arrest in infantsLia Crotti, Christopher N Johnson, Elisabeth Graf, et al.
Pageof 15

Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
Journal of Medicinal Chemistry|November 29, 2014
Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profilesJohn Skidmore, Jag Heer, Christopher N Johnson, et al.
Journal of Medicinal Chemistry|July 29, 2015
Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAPGianni Chessari, Ildiko M Buck, James E H Day, et al.
Nature Communications|January 30, 2016
Climate change not to blame for late Quaternary megafauna extinctions in AustraliaFrédérik Saltré, Marta Rodríguez-Rey, Barry W Brook, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinaseChristopher N Johnson, Valerio Berdini, Lijs Beke, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper KinaseChristopher N Johnson, Christophe Adelinet, Valerio Berdini, et al.
Journal of Medicinal Chemistry|August 10, 2018
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)Christopher N Johnson, Jong Sook Ahn, Ildiko M Buck, et al.
Journal of Medicinal Chemistry|October 31, 2003
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonistGregor J Macdonald, Clive L Branch, Michael S Hadley, et al.
Structure (London, England : 1993)|June 18, 2025
High throughput cryo-EM provides structural understanding for modulators of the lysosomal ion channel TRPML1Judith Reeks, Pravin Mahajan, Mellissa Clark, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2005
Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonistsMahmood Ahmed, Michael A Briggs, Steven M Bromidge, et al.
Circulation|February 8, 2013
Calmodulin mutations associated with recurrent cardiac arrest in infantsLia Crotti, Christopher N Johnson, Elisabeth Graf, et al.
Pageof 15